INP12
Breast Cancer
ClinicalActive
Key Facts
About InnoUp
InnoUp is a private, clinical-stage biotech leveraging its proprietary nanoparticle encapsulation platform to develop novel oral drug delivery solutions. Its pipeline includes two clinical-stage programs: an oral peanut allergy vaccine (INP20) and an oral formulation of paclitaxel for breast cancer (INP12). The company's technology aims to enhance drug bioavailability and enable mucosal immunization, positioning it in the high-growth nanomedicine and drug delivery sectors.
View full company profileOther Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Antifibrotic Therapy Program | MeCo Diagnostics | Pre-clinical |
| inPROBE for HER2 | SDS Optic | Clinical Investigation |
| ACT‑BC1 | Anthrocell | Preclinical |
| APA-1000 Breast Thermotherapy System | Medifocus | Phase III |
| Early‑Detection Breast Cancer Screening | Karkinos Healthcare | Market |
| Unnamed Breast Cancer Program | Click Therapeutics | Pilot/Phase 2 |
| Lerociclib (Lerocliclib) | Chemogenics BioPharma | Phase 3 |
| AT-017 | Asieris Pharmaceuticals | Not Specified |
| CDK2 inhibitor | Acellera | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| Maveropepimut-S (MVP-S) | BioVaxys | Clinical Evaluation |
| Cannabics® BRST-33 | CNBX Pharmaceuticals | Discovery |